荧光原位杂交技术分析人结肠菌群方法研究

建立荧光原位杂交技术分析人体内结肠菌群的方法。取受试者新鲜粪便 ,选用 5种特异性的 16SrRNA寡核苷酸探针 ,检测粪便样本收集后的保存时间、温度 ,离心条件及样本固定液存放时间对杂交计数结果的影响。结果建立最佳实验条件为 :粪便样本收集后应尽快在 4℃下保存 ,放置时间不要超过 12小时即作处理 ;样本的适宜离心条件为 70 0g 2分钟 ;样本用多聚甲醛固定后在 - 80℃下存放时间不要超过 5个月。该方法具有较好的稳定性 ,可以有效地检出个体之间结肠菌群的差异。     

A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox® in the treatment of cervical dystonia

OBJECTIVE—This study was designed toestablish whether a ratio of three units of Dysport^® isequivalent to one unit of Botox^® for the treatment ofcervical dystonia.
METHODS—Patients with predominantly rotationalcervical dystonia, and a minimum of four previous Botox treatments,were randomised to receive either the clinically indicated dose ofBotox or three times that dose in Dysport units. Study botulinum toxinwas administered in a double blind fashion, to one or more clinicallyindicated muscles, at one or more sites per muscle. Patients returnedfor assessment two, four, eight, and 12 weeks after treatment.
RESULTS—A total of 73 patients (Dysport, 38;Botox, 35) were entered. The Dysport group received a mean (SD) dose of477 (131) (range 240-720) Dysport units, and the Botox group receiveda mean (SD) dose of 152 (45) (range 70-240) Botox units. The mean(SEM) post-treatment Tsui scores for the Dysport group (4.8 (0.3)) andthe Botox group (5.0 (0.3)) were not statistically different (p=0.66).The study had 91% power to detect a clinically significant differenceof two points. Both groups showed substantial improvement in Tsui scoreby week 2 (mean (SD); Dysport, 46 (28)%; Botox, 37 (28)%), with apeak effect at week 4 (mean (SD); Dysport, 49 (29)%; Botox, 44 (28)%). A similar response profile was seen for other assessments ofefficacy. The duration of effect, assessed by time to retreatment, wasalso similar (mean (SD); Dysport, 83.9 (13.6) days; Botox, 80.7 (14.4)days; p=0.85). During the study 22 of 38 (58%) Dysport patientsreported 39 adverse events, and 24 of 35 (69%) Botox patients reported56 adverse events (p=0.35). A global assessment of efficacy and safetyconsidered that 29 of 38 (76%) Dysport patients and 23 of 35 (66%)Botox patients were treatment successes (p=0.32).
CONCLUSION—Patients with predominantly rotationalcervical dystonia treated with the clinically indicated dose of Botoxor three times that dose in Dysport units show similar improvements anddo not have significantly different safety profiles.